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Edited by Hans-Dieter KlenkAbstract The CC chemokine receptor 5 (CCR5) is a major co-
receptor for human immunodeﬁciency virus (HIV) and CCR5
mutants lacking the carboxy (C)-terminus interfere with HIV
infection. Therefore, we analysed the C-terminus of CCR5 and
here describe Jena-Muenchen 4 (JM4), a novel CCR5-interact-
ing protein. JM4 is membrane-associated, co-precipitates with
CCR5, and is ubiquitously expressed. It shares about 62% se-
quence similarity with JWA and glutamate transporter-associ-
ated protein 3-18 (GTRAP3-18), a regulator of an amino acid
transporter. JWA, like JM4, is a four-transmembrane protein,
which binds to the CCR5 receptor. Furthermore, JM4, JWA,
and GTRAP3-18 co-localise and heterodimerise indicating a
functional relationship. JM4 co-localises with calnexin in the
endoplasmic reticulum and with the mannose 6-phosphate recep-
tor in the Golgi. JM4 and GTRAP3-18 harbor a Rab-acceptor
motif, indicating a function in vesicle formation at the Golgi
complex. In conclusion, we describe a CCR5-interacting protein,
which is suggested to function in traﬃcking and membrane local-
isation of the receptor, possibly also other receptors or amino
acid transporters.
 2005 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All right reserved.
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reticulum; Golgi1. Introduction
The CC chemokine receptor 5 (CCR5) belongs to the super-
family of the G protein-coupled receptors (GPCRs), which are
seven-transmembrane proteins. Chemokine receptors play a
crucial role in the regulation of inﬂammatory processes. Most
importantly, the chemokine receptors CCR5 and CXCR4 have
been identiﬁed as the two major co-receptors for the human
immunodeﬁciency virus type 1, HIV-1, which infects CD4+
target cells [1–6]. CCR5 is expressed on memory T lympho-Abbreviations: CCR5, CC chemokine receptor 5; GPCR, G protein-
coupled receptor; HIV-1, human immunodeﬁciency virus type 1; N,
amino; C, carboxy; ER, endoplasmic reticulum; TGN, trans-Golgi
network; M6PR, mannose 6-phosphate receptor; GTRAP3-18, gluta-
mate transporter-associated protein 3-18; EAAC1, excitatory amino
acid carrier 1; ARF, ADP-ribosylation factor; ARL, ARF-like; PRA1,
prenylated Rab-acceptor 1; HA, hemagglutinin; VSV, vesicular sto-
matitis virus; CDD, conserved domain database
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doi:10.1016/j.febslet.2005.02.037cytes, macrophages, and dendritic cells and is mainly associ-
ated with transmission of viruses during primary infection
[2], while CXCR4 seems to be important at later stages of
the disease [7,8].
Mutations in the CCR5 receptor have been shown to alter
cellular signalling and HIV infection. The key role of CCR5
in HIV pathogenesis is demonstrated by the fact that individ-
uals homozygous for a 32-base pair deletion in the CCR5 gene
are almost completely protected from HIV pathogenesis [9].
This 32-base pair deletion results in a carboxy (C)-terminally
severely truncated protein, termed CCR5D32. A second natu-
rally occurring mutant receptor, termed CCR5-893(), lacks
its cytoplasmic C-terminus. Like CCR5D32, this truncated
receptor is not eﬃciently expressed at the cell surface and inter-
feres with HIV infection [10]. Evidence for the role of the cyto-
plasmic tail in receptor traﬃcking to the plasma membrane has
recently been demonstrated for the CCR2 receptor isoforms
[11]. Furthermore, the palmitoylation of the C-terminal tail
of CCR5 has a signiﬁcant inﬂuence on targeting the receptor
to the plasma membrane, on signalling, internalisation, and
intracellular traﬃcking [12–15].
Here, we identiﬁed a novel binding protein of CCR5, which
has been designated as JM4, Jena-Muenchen 4, in the database
(NCBI Protein Database = NCB Accession No. CAA06753),
no function has been assigned to this protein so far. Sequence
prediction suggested that JM4 is a four-transmembrane-span-
ning protein with a preferential localisation at the endoplasmic
reticulum (ER). JM4 shares sequence similarity with human
JWA and the rat homologue glutamate transporter-associated
protein 3-18 (GTRAP3-18), which regulates glutamate uptake
by interacting with the ten-transmembrane-spanning excit-
atory amino acid carrier 1 (EAAC1) [16]. We show that
JWA, like JM4, binds to CCR5. Based on sequence, structure,
and function similarities, JM4, JWA, and GTRAP3-18 are re-
lated and localise in the ER and vesicular structures. They
associate with CCR5 and are suggested to function in traﬃck-
ing and membrane localisation of the receptor.2. Materials and methods
2.1. Plasmid construction
The C-terminus of the human CCR5, encoding amino acids 295–
352, was excised from pBABE.CCR5 (AIDS Research and Reference
Reagent Program) and subcloned into the EcoRI/SalI sites of
pGBT9pheS using a EcoRI–SfaI linker. The pGBT9pheS is a deriva-
tive of the pGBT9 bait vector containing a Gal4–DNA binding do-
main (Clontech) that was modiﬁed to add positive selection
properties (M. Buchert, unpublished data) [17].
Gene mutations were introduced by QuickChange site-directed
mutagenesis according to the manufacturers instructions (Stratagene).blished by Elsevier B.V. All rights reserved.
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NAI.CCR5 (AIDS Research and Reference Reagent Program) and in-
serted into the pcDNA3 vector (Invitrogen) using a HindIII–BamHI
linker including an amino (N)-terminal hemagglutinin (HA)-epitope
to create pcDNA3–HA–CCR5. The JM4-encoding sequence was ex-
cised from the pACT.1 plasmid (JM4, amino acids 7–178) and sub-
cloned into the BamHI restriction site of the pcDNAI-based
expression vector pSuper Vesicular Stomatitis Virus, VSV (pSVSV;
C. Hovens, unpublished data). A VSV–JM4 linker was inserted in-
frame with the 5 0-VSV-sequence to obtain pSVSV–JM4 that encodes
the full-length VSV–JM4.
JM4 and JWA cDNAs were subcloned into a pcDNA3 vector con-
taining two Myc-epitope encoding sequences (pcDNA3-2 ·Myc; E.
Haas, own unpublished data). JM4 and JWA were ampliﬁed with Ac-
cess RT-PCR kit (Promega) using pSVSV–JM4 and RNA extracts
from human neuroblastoma cell line SHSY-5Y as templates, respec-
tively. The PCR products were subcloned into a pCR2.1-TOPO vector
using a TOPO TA cloning kit (Invitrogen) and inserted in the
pcDNA3-2 ·Myc vector to create pcDNA3-2 ·Myc–JM4 and -JWA.
The GTRAP3-18–HA expression plasmid was kindly received from
J. Rothstein (Johns Hopkins University, Baltimore, USA) [16].
All linker and primer sequences can be obtained upon request.
2.2. Yeast two-hybrid techniques
Y153 yeast cells were transformed with the bait plasmid and a hu-
man pre-B cell cDNA library cloned in pACT as prey (kindly provided
by S. Elledge, Harvard Medical School, Boston, USA) [18,19]. Trans-
formants were screened for histidine prototrophy in the presence of
10 mM 3-aminotriazole (Sigma). Interaction was demonstrated by
lacZ+ transformants.2.3. Northern blot analysis
A JM4-probe labelled with [a-32P]-dCTP (Amersham Biosciences)
was prepared by random priming of a JM4-fragment using RadPrime
DNA labelling system (Invitrogen) as described in the manufacturers
protocol. A human 12-lane multiple tissue Northern blot was used to
analyse mRNA levels of JM4 according to the manufacturers instruc-
tions (Clontech). The membrane was exposed to imaging plates, which
were analysed with a PhosphorImager (Amersham Biosciences) using
ImageQuant software.
The blot was stripped by boiling in 5 mM potassium phosphate buf-
fer and reprobed with a b-actin probe to conﬁrm equivalent amounts
of RNA.2.4. Cell culture and transfection
The human embryonic kidney-, HEK-, 293 and HeLa cell lines were
grown in Dulbeccos modiﬁed eagles medium (DMEM; Gibco) sup-
plemented with 10% fetal calf serum (FCS; Seratec). Cf2Th cells that
stably express a codon-optimised, C-terminally epitope-tagged CCR5
(synCCR5-C9) were provided by J. Sodroski (Dana Farber Cancer
Institute, Boston, USA) and maintained as described [20].
Cells were transfected using LipofectAMINE 2000 (Gibco) or a
modiﬁed calcium phosphate transfection protocol [21].
HEK-293 cells transfected with HA–CCR5 encoding construct were
selected for stable protein expression with 1 mg/ml G418 sulfate (Cal-
biochem) and sorted for CCR5 cell surface expression by ﬂuorescence-
activated cell sorting (FACS).
2.5. Cell lysis
For preparation of membrane and cytoplasmic cellular fractions, the
cells were harvested in hypotonic lysis buﬀer (HLB; 10 mM Tris–HCl
(pH 7.5), 10 mM NaCl, 0.2 mM EDTA, 1 mM DTT) supplemented
with inhibitors (25 mM b glycerol-phosphate, 25 mM NaF, 1 mM
Na3VO4, 1 mM PMSF, 1 mM benzamidine, 10 lM pepstatin, trasylol
(500 Kalikrein inactivator units), 5 lg/ml leupeptin). Cell lysates were
prepared by Dounce homogenisation and centrifuged at 500 · g for
5 min to eliminate nuclei and debris. The supernatant was subjected
to ultracentrifugation at 65 000 rpm for 60 min using the TLA-100.2
ﬁxed angle rotor in Optima TL-100 ultracentrifuge (Beckman). The
supernatant (cytoplasm) was adjusted to 100 mM NaCl and 0.5%
Nonidet P-40. The membrane pellet was resolubilised in NETN buﬀer
(50 mM Tris–HCl (pH 7.5), 100 mM NaCl, 200 mM EDTA, 0.5%
Nonidet P-40, 1 mM DTT, supplemented with inhibitors).For native puriﬁcation of CCR5, cells were lysed in solubilisation
buﬀer (100 mM (NH4)2SO4, 20 mM Tris–HCl (pH 7.5), 10% Glycerol,
0.5% Cymal-5 (Anatrace, Maumee, USA), supplemented with
inhibitors).
All lysis steps were performed at 4 C, cell lysates were cleared by
centrifugation, and protein concentrations of the supernatants were
determined using the Protein Assay Kit (Bio-Rad).
2.6. Antibodies
The following antibodies were used: anti-VSV antibody: mouse
monoclonal P5D4 (Sigma); anti-CCR5 antibodies: mouse monoclonal
2D7 (AIDS Research and Reference Reagent Program), ﬂuorescein
isothyocyanate (FITC)-conjugated 2D7 (BD Pharmingen), goat poly-
clonal C20 (Santa Cruz); anti-HA antibodies: monoclonal mouse
12CA5 (Sigma), monoclonal rat 3F10 (Boehringer), polyclonal rabbit
Y11 (Santa Cruz); anti-Myc antibodies: mouse monoclonal 9E1O
(Roche), rabbit polyclonal A14 (Santa Cruz); HRP-conjugated anti-
bodies: anti-mouse, anti-rabbit (Amersham Biosciences), anti-goat
(Santa Cruz); FITC-conjugated anti-rabbit antibody, tetramethylrhod-
amine isothiocyanate (TRITC)-conjugated anti-mouse antibody
(Molecular Probes, Jackson ImmunoResearch Lab.); rabbit anti-caln-
exin antibody; rabbit anti-P300 mannose 6-phosphate receptor
(M6PR) antibody [22].2.7. Immunoprecipitation and Western blotting
Proteins were immunoprecipitated with antibody-precoupled se-
pharose-beads and eluted in SDS sample buﬀer (62.5 mM Tris–HCl
(pH 6.8), 10% glycerol, 2% SDS, 0.1% bromphenol blue, 50 ll/ml b-
mercaptoethanol) for 5 min at 95 C or 60 min at 55 C. Proteins were
separated according to their size on 12.5% SDS-polyacrylamide gels
and transferred to nitrocellulose membranes (Amersham Biosciences).
Proteins were detected using speciﬁc antibodies and visualised with
HRP-conjugated antibodies by enhanced chemiluminescence (Amer-
sham Biosciences).2.8. FACS analysis
HEK-293 cells expressing CCR5 wild-type were sorted in cold PBS
supplemented with 1% FCS using the FITC-conjugated 2D7 antibody.
Cell sorting was performed on a FACStar cell sorter (Becton Dickin-
son). Cells were analysed by ﬂow cytometry using a FACScalibur ﬂow
cytometer and CellQuest software (Becton Dickinson).2.9. Confocal immunoﬂuorescence microscopy
Cells were ﬁxed with 3% paraformaldehyde for 15 min at 25 C.
Intracellular antigens were detected after permeabilisation with 0.5%
Triton X-100 for 2.5 min at 25 C. Cells were incubated with speciﬁc
antibodies in PBS containing 5% new born calf serum (NCS; Invitro-
gen) for 60 min, followed by an incubation with a chromophore-conju-
gated secondary antibody for 60 min. Coverslips were mounted with
Mowiol (Calbiochem) and images were collected on a Leica TCS4D
confocal microscope (Leica Microsystems) and analysed using IM-
ARIS bitplane software.3. Results
3.1. Identiﬁcation of the interaction of CCR5 with JM4
A Gal4-dependent yeast two-hybrid screen was performed
with the C-terminus of the CCR5, amino acids 295–352, using
a human B-cell cDNA library and resulted in the identiﬁcation
of an interacting protein. The corresponding cDNA was se-
quenced and identiﬁed in the database as JM4, lacking six
N-terminal amino acid residues. JM4 did not bind to a deletion
mutant of the CCR5 C-terminus (amino acids 295–320; data
not shown).
3.2. JM4 expression proﬁle
A human multiple tissue Northern blot was hybridised with
a [32P]-labelled JM4-speciﬁc probe. Analysis of JM4 mRNA
Fig. 1. JM4, a novel CCR5-interacting protein. Tissue distribution of
JM4. A human multiple tissue Northern blot (Clontech) was hybri-
dised with a [32P]-labelled probe derived from human JM4 (top),
stripped, and reprobed with a b-actin probe (bottom).
Fig. 2. Interaction of JM4 and CCR5. (A) Interaction of full-length
CCR5 with JM4 in mammalian cells. HEK-293 cells or HEK-293 cells
stably expressing HA–CCR5 were transfected with plasmids encoding
Myc–JM4 or empty vector control as indicated. Cells were lysed and
HA–CCR5 was immunoprecipitated using an anti-HA antibody
(12CA5). Proteins were separated according to their size by 12.5%
SDS–PAGE and transferred to a nitrocellulose membrane. Protein
expression and co-precipitation of Myc–JM4 with HA–CCR5 were
analysed using anti-Myc and anti-HA antibodies as indicated. The
result was reproducible in several independent experiments. Numbers
on the left correspond to molecular weight marker sizes in kilodalton.
DL, direct cell lysate; IP, immunoprecipitation; l.c., light chain; h.c.
heavy chain. (B) Cf2Th cells stably expressing a codon-optimised
CCR5 with a C-terminal epitope tag (synCCR5-C9) [20] were
transfected with plasmids encoding VSV-epitope-tagged JM4 (+) or
empty plasmid control (). Membrane (Mem) and cytoplasmic (Cyt)
fractions of cellular lysates were prepared by ultracentrifugation.
Immunoprecipitation of synCCR5-C9 was carried out using an
antibody directed against the second extracellular loop of CCR5
(2D7). Proteins were separated according to their size by 12.5% SDS–
PAGE and transferred to a nitrocellulose membrane. Proteins were
detected using anti-VSV and anti-CCR5 antibodies as indicated.
M. Schweneker et al. / FEBS Letters 579 (2005) 1751–1758 1753expression in 12 human tissues revealed one single transcript of
about 1.2 kb (Fig. 1). Among the 12 adult tissues the JM4-
transcript is expressed nearly ubiquitously. For loading control
a b-actin probe was used (2.0 and 1.8 kb).
3.3. Association of JM4 with CCR5 and cellular membranes
To verify the interaction in mammalian cells, JM4 was ex-
pressed in HEK-293 cells selected and sorted for stable expres-
sion of HA–CCR5. Using these cells, we were able to
demonstrate the speciﬁc interaction of JM4 with CCR5 by
co-immunoprecipitation (Fig. 2A, upper part, lane 4).
We wanted to conﬁrm the predicted membrane association
of JM4 and therefore analysed its subcellular localisation by
cellular fractionation. Canine thymocytes, Cf2Th cells, trans-
fected with a codon-optimised CCR5 designed for enhanced
gene expression and selected for stable receptor expression
[20] were transfected with a plasmid encoding VSV–JM4 or
empty vector control. Proteins were immunoprecipitated from
membrane (Mem) and cytoplasmic (Cyt) fractions prepared by
ultracentrifugation and JM4 and CCR5 detected by Western
blot analysis. As shown in Fig. 2B, JM4 is associated with
the membrane fraction, which contains plasma membranes
and intracellular membranes (lane 2). This result supports
the prediction that JM4, due to its transmembrane domains,
is associated with cellular membranes. JM4 is not detected in
the cellular cytoplasmic fraction (lane 4). The interaction of
JM4 and the C-terminus of CCR5, as identiﬁed in yeast and
veriﬁed with full-length proteins in HEK-293 cells, was further
conﬁrmed here in the Cf2Th mammalian cell line. A complex
of CCR5 and JM4 is shown by co-immunoprecipitation of
JM4 with CCR5 from the membrane fraction (lane 6). As de-
scribed for Cf2Th cells and other cell lines, expression of a
CCR5 protein with lower molecular mass was detectable in
parallel with the mature CCR5 receptor (Fig. 2B) [20].
3.4. JM4-related proteins and cellular localisation
We further studied JM4 by sequence analyses. JM4 was so
far uncharacterised and no biological function has been attrib-
uted to the protein. The full-length sequence of the JM4 pro-
tein is shown in Fig. 3A, top. The protein is predicted to be
178 amino acids in size. A transmembrane prediction using
the TMHMM program (v. 2.0) [23] and hydrophobicity plots
suggested that four-transmembrane-spanning helices. Theseare indicated by grey bars. A database search for related pro-
teins identiﬁed several proteins throughout diﬀerent species,
which are aligned in Fig. 3A. All of these share sequence
Fig. 3. JM4, JWA, and GTRAP3-18 share sequence and structure homologies and co-localise within the cell. (A) Alignment of JM4 and related
proteins from diﬀerent species using the program MacVectore 7.1. The shaded regions indicate conserved amino acid residues and grey bars
represent the four predicted transmembrane helices of JM4. The structural homology of JM4 (amino acids 1–178) and JWA (amino acids 1–188) is
reﬂected in the transmembrane plots shown below (y-axis: transmembrane probability; x-axis: amino acid position). Potential transmembrane helices
of JM4 and JWA are shown in red (TMHMM (v. 2.0)) [23]. (B) Co-localisation of JM4, JWA, and GTRAP3-18. HeLa cells were transfected with
plasmids as indicated (top: VSV–JM4 and Myc–JWA; bottom: VSV–JM4 and GTRAP3-18–HA). For detection by immunoﬂuorescence the
appropriate antibodies were used (top: mouse anti-VSV, rabbit anti-Myc; bottom: mouse anti-VSV, rabbit anti-HA) followed by incubation with
TRITC-conjugated (red) anti-mouse and FITC-conjugated (green) anti-rabbit antibodies. The yellow colour in the merged pictures indicates co-
localisation of the proteins (right). (C) Cellular distribution of JM4. HeLa cells were transiently transfected with a vector encoding VSV–JM4.
Cellular localisation of proteins was analysed by immunoﬂuorescence using speciﬁc antibodies. Expression of JM4 is shown in red, cellular calnexin
(marker of the endoplasmic reticulum) or M6PR (marker of trans-Golgi and endosomes) are visualised in green. Cellular co-localisation of JM4 with
calnexin (top) or with M6PR (bottom) results in yellow colour in the merged pictures (right).
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transmembrane helices in a pattern similar to JM4. Thus, the
protein is conserved. The structural homology of JM4 and
JWA is reﬂected in the transmembrane plots (Fig. 3A, bot-
tom). GTRAP3-18, the rat homologue of JWA binds to and
inhibits the function of the glutamate transporter EAAC1
[16]. GTRAP3-18 and its human homologue JWA share 92%
sequence identity at the protein level. JM4 shows 42% se-
quence identity and an additional 21% protein sequence simi-
larity with JWA.
Since the human proteins JM4 and JWA and its rat homo-
logue GTRAP3-18 share sequence and structure homologies,
we analysed their cellular localisation using confocal laser
scanning microscopy. VSV–JM4, Myc–JWA, and GTRAP3-
18–HA were expressed pairwise in HeLa cells and proteins
were detected using the respective antibodies directed against
the epitope tags and ﬂuorescence-labelled secondary antibod-
ies. The co-localisation of protein pairs is indicated by the yel-
low colour in the merged pictures (Fig. 3B).
We wanted to further deﬁne the cellular distribution of JM4.
Prediction of protein sorting signals and localisation sites inamino acid sequences, PSORTII analysis, predicted a 56%
probability for JM4-association with the ER and about 10%
for each other compartment, for plasma membrane, Golgi,
or mitochondrial or vacuolar localisation. Based on this pre-
diction and the relationship of JM4 to proteins of the intracel-
lular traﬃcking machinery, we analysed the intracellular
localisation of JM4 in comparison with calnexin, which resides
in the ER, and the M6PR, a marker of trans-Golgi and endo-
somes. Immunoﬂuorescence analysis indicated that JM4 is co-
localised with calnexin and M6PR in granular structures, (Fig.
3C, top and bottom, respectively). These results substantiate
the presence of JM4 in the ER and trans-Golgi network
(TGN). Similar results were obtained in COS cells (data not
shown).
3.5. Relationship of JM4, GTRAP3-18, and JWA as
demonstrated by heterodimerisation
We had noticed that JM4, like GTRAP3-18 [16], formed
multimeric complexes. To test this, HEK-293 cells were trans-
fected with JM4-encoding constructs, either VSV- or Myc-epi-
tope-tagged at their N-termini, or empty vector control
Fig. 3 (continued)
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after immunoprecipitation from cellular lysates using an anti-
VSV antibody (Fig. 4A, lane 4). Not only monomers of JM4,
but also dimers and trimers of JM4 were co-precipitated. Sim-
ilarly, VSV–JM4 was detected by Western blotting after pre-
cipitation of Myc–JM4 (data not shown). The formation of
dimers and trimers is still apparent after heat-denaturation
and non-native SDS–PAGE, indicating that the complex for-
mation is of high stringency. JM4, JWA, and GTRAP3-18
form hetero-complexes as shown by pairwise expression of
the proteins in HEK-293 cells and co-immunoprecipitation
with the respective antibodies. Thus, JM4, JWA, and
GTRAP3-18 are structurally related, located in the same struc-
tures within the cell (Fig. 3B), and can physically interact with
each other (Fig. 4B).
JWA also resembles JM4 in its ability to bind to the
CCR5 receptor. HEK-293 cells stably expressing the CCR5
receptor were transfected with plasmids encoding Myc–
JM4 or Myc–JWA and used for co-immunoprecipitationstudies. Indeed, JM4 and JWA were both able to bind to
the CCR5 receptor (Fig. 4C, middle panel, lanes 4 and 6,
respectively).
3.6. JM4 aﬀects CCR5 protein levels
To analyse whether JM4 aﬀects levels of CCR5 at the cell
surface, HEK-293 cells were co-transfected with plasmids
encoding HA–CCR5 andMyc–JM4 or control. Receptor levels
at the plasma membrane were analysed by FACS. About 50%
reduction of CCR5 protein at the plasma membrane was de-
tected in cells overexpressing JM4 when compared to CCR5
control cells (Fig. 5A, grey and darker line, respectively). The
eﬀect was further analysed for protein levels of CCR5 in total
cell lysates by Western Blot. HEK-293 cells were co-transfected
with plasmids encoding synCCR5-C9 and JM4 or empty con-
trol plasmid. CCR5 was precipitated from whole cellular ly-
sates using a conformation-dependent anti-CCR5 antibody
(2D7) or an antibody directed against the C9-epitope tag fused
to the C-terminus of CCR5 (1D4). CCR5 protein levels were
Fig. 4. (A) JM4 forms homo-multimers. HEK-293 cells were transfected with VSV–JM4, Myc–JM4, or empty vector control plasmids as indicated.
Cell lysates were immunoprecipitated using an anti-VSV antibody (P5D4). Proteins were separated according to their size by 12.5% SDS–PAGE,
transferred to a nitrocellulose membrane, and the co-precipitating Myc–JM4 detected using an anti-Myc antibody. Numbers on the left correspond
to molecular weight marker sizes in kilodalton. (For abbreviations see Fig. 2.) (B) Hetero-multimerisation of JM4, JWA, and GTRAP3-18. HEK-293
cells were transfected with plasmids encoding VSV–JM4, Myc–JWA, GTRAP3-18–HA, or empty vector control as indicated. Subsequently, cells
were lysed and proteins immunoprecipitated using a mouse anti-VSV antibody (P5D4). Proteins were separated according to their size by SDS–
PAGE and transferred to nitrocellulose membranes for immunoblotting with anti-VSV, anti-Myc, or anti-HA antibodies as indicated. (C)
Interaction of CCR5 with JM4 and JWA. HEK-293 cells (control) or HEK-293 stably expressing HA–CCR5 (CCR5) were transfected with Myc–
JM4, Myc–JWA, or empty vector control plasmids. After cell lysis, HA–CCR5 was precipitated using an anti-HA antibody (12CA5). Proteins were
separated according to their size by 12.5% SDS–PAGE and transferred to a nitrocellulose membrane. HA–CCR5, Myc–JM4, and Myc–JWA were
detected using the anti-HA and anti-Myc antibodies, respectively. The results were conﬁrmed in two independent experiments.
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6) when compared to cells co-transfected with empty plasmid
control with some preferential reduction of the upper mature
form of CCR5 (Fig. 5B, lanes 3 and 4).4. Discussion
Here, we describe the JM4 protein, which interacts with the
C-terminus of the CCR5 receptor. Moreover, the JM4-related
protein JWA also associates with CCR5. Previously, it hasbeen shown that the JM4-related rat protein GTRAP3-18
binds to the amino acid transporter EAAC1 [16]. Therefore,
JM4, JWA, and GTRAP3-18 might comprise a family of pro-
teins that interact not only with CCR5, but also with other
GPCRs or transmembrane-spannning proteins. Other
GPCR-interacting proteins such as b-arrestins or members of
the family of GPCR-associated sorting proteins (GASP) have
been shown to bind and regulate not only one speciﬁc but sev-
eral GPCR proteins [24–26].
JM4 is ubiquitously expressed and computer-based data
analyses predict that JM4 is a four-transmembrane-spanning
Fig. 5. Co-transfection of JM4 and CCR5 aﬀects receptor protein
levels. (A) CCR5 expression levels at the cell surface of HEK-293 cells
co-transfected with plasmids encoding HA–CCR5 and Myc–JM4 (grey
line) or HA–CCR5 and control plasmid (darker line) were determined
by ﬂow cytometry using the FITC-conjugated anti-CRR5 antibody
2D7. Staining with isotype control antibody is shown in shaded
histogram. The results were reproducible in several experiments. (B)
HEK-293 cells were transfected with plasmids encoding synCCR5-C9
and Myc–JM4 or empty vector control as indicated. Cells were lysed
and CCR5 was immunoprecipitated using a conformation-dependent
or -independent antibody (2D7 and 1D4, respectively) as indicated.
Proteins were separated according to their size by SDS–PAGE and
transferred to a nitrocellulose membrane for immunoblotting with
anti-CCR5 antibody (C20). (For abbreviations see Fig. 2.)
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analyses of JM4 and the related protein JWA show localisa-
tion of these proteins in a network-like structure, resembling
the ER and the Golgi. In particular, JM4 co-localises with
calnexin and M6PR. Calnexin is as an integral membrane com-
ponent of the ER and acts as a molecular chaperone involved
in quality control of newly synthesised proteins and protein
sorting in the secretory pathway [27,28]. The second protein,
M6PR, is located particularly in the TGN and endosomes
and functions primarily in the transport of M6P-containing
glycoproteins from the TGN to endosomes or lysosomes
[29]. JM4 must interact with CCR5 at intracellular membranes
during traﬃcking possibly when the receptor is traﬃcked from
the ER, through the Golgi apparatus to the plasma membrane,
because we did not detect JM4 at the plasma membrane by
immunoﬂuorescence analyses (Fig. 3B) as it has previously
been reported for GTRP3-18 [20].
Sequence analyses suggested a relationship of JM4 with an
interaction partner of an ADP-ribosylation factor (ARF) fam-ily member [30]. ARF and ARF-like (ARL) proteins belong to
a large family of GTPases, some of which have been demon-
strated to be involved in the formation of transport vesicles
and intracellular traﬃc [31–33]. Analyses using the conserved
domain database, CDD [34], showed signiﬁcant similarities
of JM4 with a family of proteins bearing a prenylated Rab-
acceptor 1 (PRA1) motif. This family of proteins includes also
GTRAP3-18. PRA1 regulates vesicle biogenesis at the Golgi
[35] and like ARFs associates with membranous vesicles dur-
ing assembly and transport [36]. Furthermore, PRA1 has just
recently been shown to interact with a GPCR [37], underscor-
ing its relationship with JM4.
No obvious cellular phenotype could be detected after
down-regulation of JM4 using small interfering RNAs even
though RNA interference clearly reduced JM4 at the mRNA
and protein level (data not shown). Loss of JM4 function is
compensated for by related proteins, such as JWA or other un-
known proteins.
Considering the putative biological function of JM4 and
JWA in intracellular transport, we analysed cell surface expres-
sion of CCR5 after overexpression of JM4 in a transient co-
transfection system. Indeed, JM4 reduced CCR5 levels at the
plasma membrane but also in cellular lysates, where especially
the CCR5 form of higher molecular weight was aﬀected (Fig.
5). This suggests that JM4 may be a guardian for incorrect bal-
ance of proteins, their folding or other parameters involved in
transport and may induce proteasomal degradation. This
needs to be further analysed.
JM4 aﬀected not only expression and cell surface localisa-
tion of CCR5 but also of other membrane proteins such as
CXCR4 or CD4, but not the cytoplasmic green ﬂuorescence
protein (data not shown). This has also been reported for par-
allel co-transfection of other membrane proteins [37].
In summary, we identiﬁed a novel CCR5-interacting protein
JM4, which, based on structural and functional similarities to
JWA and GTRAP3-18 and on computer-database-assisted
predictions, is suggested to play a role during protein transport
through the ER and Golgi to the plasma membrane. JM4
function may not be restricted to CCR5, but may aﬀect also
other transmembrane proteins, as suggested by its similarity
to GTRAP3-18, a known regulator of the plasma mem-
brane-associated glutamate transporter EAAC1.
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